Aptose Biosciences is biotechnology company developing agents to treat medical needs in cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Co.'s product pipeline includes cancer drug candidates that exert potent activity as stand-alone agents and that improve the activities of other anticancer agents without causing overlapping toxicities. Co.'s clinical-stage programs include: CG-806, which is a mutation-agnostic FMS-like tyrosine kinase 3 / Bruton's tyrosine kinase inhibitor; and APTO-253, which is a small molecule MYC oncogene inhibitor. The APTO stock yearly return is shown above.
The yearly return on the APTO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the APTO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|